ATE195076T1 - Verfahren zur isolierung von haemopnilus influenzae protein-e - Google Patents

Verfahren zur isolierung von haemopnilus influenzae protein-e

Info

Publication number
ATE195076T1
ATE195076T1 AT94100492T AT94100492T ATE195076T1 AT E195076 T1 ATE195076 T1 AT E195076T1 AT 94100492 T AT94100492 T AT 94100492T AT 94100492 T AT94100492 T AT 94100492T AT E195076 T1 ATE195076 T1 AT E195076T1
Authority
AT
Austria
Prior art keywords
haemopnilus
isolation
extracting
protein
influenzae
Prior art date
Application number
AT94100492T
Other languages
English (en)
Inventor
Bruce A Green
Gary W Zlotnick
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE195076T1 publication Critical patent/ATE195076T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT94100492T 1989-03-09 1990-03-09 Verfahren zur isolierung von haemopnilus influenzae protein-e ATE195076T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32097189A 1989-03-09 1989-03-09

Publications (1)

Publication Number Publication Date
ATE195076T1 true ATE195076T1 (de) 2000-08-15

Family

ID=23248627

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90905112T ATE110965T1 (de) 1989-03-09 1990-03-09 Impfstoffe gegen hämophilus influenzae.
AT94100492T ATE195076T1 (de) 1989-03-09 1990-03-09 Verfahren zur isolierung von haemopnilus influenzae protein-e

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT90905112T ATE110965T1 (de) 1989-03-09 1990-03-09 Impfstoffe gegen hämophilus influenzae.

Country Status (13)

Country Link
US (4) US5601831A (de)
EP (2) EP0462210B1 (de)
JP (1) JP2955014B2 (de)
KR (1) KR100188323B1 (de)
AT (2) ATE110965T1 (de)
AU (1) AU648251B2 (de)
CA (1) CA2047681C (de)
DE (2) DE69012318T2 (de)
DK (2) DK0462210T3 (de)
ES (2) ES2063965T3 (de)
FI (1) FI914241A0 (de)
NO (1) NO913518L (de)
WO (1) WO1990010458A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
AU2699192A (en) * 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
NZ306316A (en) * 1995-04-17 2001-06-29 Smithkline Beecham Biolog S use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
ATE334673T1 (de) * 1997-11-12 2006-08-15 Hoffmann La Roche Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
US6255050B1 (en) * 1998-05-22 2001-07-03 Lorne Park Research, Inc. Dynamic hybridization system
MXPA01013264A (es) * 1999-06-25 2002-06-04 American Cyanamid Co Extracion de proteinas de membrana integral.
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
EP1210114A4 (de) * 1999-08-20 2004-01-02 Gen Hospital Corp Äusseres membranprotein a, peptidoglykan-assoziiertes lipoprotein und mureinlipoprotein als therapeutische ziele zur behandlung von sepsis
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AU8640501A (en) * 2000-07-31 2002-02-13 Univ Yale Innate immune system-directed vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
GB0025486D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6834384B2 (en) * 2001-03-14 2004-12-21 General Instrument Corporation Methods and apparatus for upgrading firmware in an embedded system
CA2446355A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
EP1404368B1 (de) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutantenformen von cholera holotoxin als adjuvans
AU2002322380B2 (en) * 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
AU2002310760A1 (en) * 2001-06-12 2002-12-23 Glaxosmithkline Biologicals S.A. Proteins derived from non-typable haemophilus influenzae (nthi) strain
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7615229B2 (en) * 2002-03-15 2009-11-10 Wyeth Holdings Corporation Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity
KR102378962B1 (ko) 2005-04-08 2022-03-28 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20070047455A (ko) * 2005-11-02 2007-05-07 삼성에스디아이 주식회사 전자 방출 표시 디바이스
EP3011969A1 (de) * 2006-03-07 2016-04-27 Vaxinnate Corporation Zusammensetzungen mit hämagglutinin, verfahren zur herstellung und verfahren zur verwendung davon
EP1915913B1 (de) * 2006-10-23 2015-11-18 Nestec S.A. Abstimmung von Geschmack und Aroma in Milchprodukten durch Biotransformation
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2657704A1 (de) * 2009-01-07 2013-10-30 Otsuka Pharmaceutical Co., Ltd. Verfahren zur Erkennung sämtlicher Haemophilus influenzae
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (de) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4220722A (en) 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4661347A (en) 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4873090A (en) * 1985-03-27 1989-10-10 Broncostat Pty. Limited Non-adjuvenated vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens

Also Published As

Publication number Publication date
JP2955014B2 (ja) 1999-10-04
ATE110965T1 (de) 1994-09-15
US5601831A (en) 1997-02-11
EP0606921B1 (de) 2000-08-02
DE69033600T2 (de) 2001-04-05
CA2047681A1 (en) 1990-09-10
ES2063965T3 (es) 1995-01-16
FI914241A7 (fi) 1991-09-09
ES2150450T3 (es) 2000-12-01
US5780601A (en) 1998-07-14
JPH07508972A (ja) 1995-10-05
EP0462210A1 (de) 1991-12-27
NO913518D0 (no) 1991-09-06
EP0462210B1 (de) 1994-09-07
AU5332690A (en) 1990-10-09
CA2047681C (en) 2000-02-01
KR100188323B1 (ko) 1999-06-01
DE69012318D1 (de) 1994-10-13
FI914241A0 (fi) 1991-09-09
US6420134B1 (en) 2002-07-16
DE69012318T2 (de) 1995-03-09
DE69033600D1 (de) 2000-09-07
WO1990010458A1 (en) 1990-09-20
US5955580A (en) 1999-09-21
NO913518L (no) 1991-10-29
AU648251B2 (en) 1994-04-21
EP0606921A1 (de) 1994-07-20
DK0462210T3 (da) 1994-10-10
DK0606921T3 (da) 2000-09-04

Similar Documents

Publication Publication Date Title
ATE195076T1 (de) Verfahren zur isolierung von haemopnilus influenzae protein-e
DE69631996D1 (de) Verfahren zur Herstellung von acylierten Proteinpuder
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
CA2005291A1 (en) Feline infectious peritonitis virus diagnostic tools
DE3667489D1 (de) Verfahren zur herstellung eines proteins.
DE3762604D1 (de) Verfahren zur herstellung von waessrigen loesungen von freiem hydroxylamin.
FI872367A7 (fi) Menetelmä N-metyylimorfoliini-N-oksidin vesiliuoksen valmistamiseksi.
DE69403210D1 (de) Verfahren zur herstellung von n-acetylneuraminsäure
DE3861738D1 (de) Verfahren zur herstellung konzentrierter waessriger farbstoffzubereitungen.
DE3582755D1 (de) Verfahren zur herstellung salzarmer, fluessiger, waessriger zubereitungen von faserreaktiven farbstoffen.
DE3780527D1 (de) Verfahren zur herstellung von 5'-guanyl-saeure.
DE3768426D1 (de) Verfahren zur herstellung von 4,4'-biphenyldicarbonsaeure.
DE3776440D1 (de) Verfahren zur herstellung von 5-aminosalicylsaeure.
DE68910771D1 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
DE3785119D1 (de) Verfahren zur herstellung von aminosaeuren.
ATE124706T1 (de) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben.
ATA297985A (de) Verfahren zur herstellung von bis-indolverbindungen enthaltenden stabilen waesserigen arzneimittelpraeparaten
AU7816487A (en) Process for concentration of an aqueous solution of amino acid
DE59002095D1 (de) Verfahren zur rueckgewinnung von schwefelsaeure.
ATA91186A (de) Verfahren zur herstellung von n-(1(s)|thoxycarbonyl-3-phenyl-propyl)-(s)-alanyl-(s)prolin und von dessen saeureadditionssalzen
DE3685603D1 (de) Verfahren zur immunologischen bestimmung von heparansulfat-proteoglykan, verfahren zur herstellung bzw. reinigung von dafuer geeignetem heparansulfat-proteoglykan aus basalmembranhaltigen geweben.
DE3581541D1 (de) Verfahren zur herstellung von zyklischen urea-derivaten.
DE68911295D1 (de) Verfahren zur herstellung von 2-oxo-3-aromatischen karbonsäure-derivaten.
DE3676899D1 (de) Verfahren zur herstellung von n-methyl-lysergol.
JPS53127808A (en) Preparation of human albumin

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time